141 related articles for article (PubMed ID: 21660951)
1. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.
Corallini F; Celeghini C; Rimondi E; di Iasio MG; Gonelli A; Secchiero P; Zauli G
J Cell Physiol; 2011 Sep; 226(9):2279-86. PubMed ID: 21660951
[TBL] [Abstract][Full Text] [Related]
2. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
4. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells.
Brändström H; Björkman T; Ljunggren O
Biochem Biophys Res Commun; 2001 Jan; 280(3):831-5. PubMed ID: 11162596
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
McGonigle JS; Giachelli CM; Scatena M
Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2.
Tsubaki M; Satou T; Itoh T; Imano M; Yanae M; Kato C; Takagoshi R; Komai M; Nishida S
Mol Cell Endocrinol; 2012 Sep; 361(1-2):219-31. PubMed ID: 22579611
[TBL] [Abstract][Full Text] [Related]
9. Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells.
Lambert C; Oury C; Dejardin E; Chariot A; Piette J; Malaise M; Merville MP; Franchimont N
J Bone Miner Res; 2007 Sep; 22(9):1350-61. PubMed ID: 17501665
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
11. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME
Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
Chamoux E; Houde N; L'Eriger K; Roux S
J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells.
Pantouli E; Boehm MM; Koka S
Biochem Biophys Res Commun; 2005 Apr; 329(1):224-9. PubMed ID: 15721297
[TBL] [Abstract][Full Text] [Related]
15. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
[TBL] [Abstract][Full Text] [Related]
16. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
17. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells.
Brändström H; Jonsson KB; Ohlsson C; Vidal O; Ljunghall S; Ljunggren O
Biochem Biophys Res Commun; 1998 Jun; 247(2):338-41. PubMed ID: 9642127
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F; Hendarmin L; Nakamura S
Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
[TBL] [Abstract][Full Text] [Related]
20. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]